What should I do if I become drug-resistant after taking Rucaparib?
If a patient develops drug resistance after taking rucaparib (Rucaparib), should communicate with the doctor or professional medical team in a timely manner and inform them of the drug resistance. Physicians will be able to assess the extent of resistance development and tailor further treatment options to the patient's specific circumstances.
Patients may need genetic testing, specificallyBRCA genes and other genes associated with sensitivity to PARP inhibitors, which will help determine whether other mutations or mechanisms in the cancer contribute to resistance. Depending on the test results, your doctor may recommend other treatment options. By using a combination of drugs with different mechanisms, such as chemotherapy drugs, immunotherapy or other targeted therapies. Treatment with this drug combination may increase therapeutic efficacy and reduce the development of drug resistance. Participate in relevant clinical trials to explore new treatment strategies and drugs. Clinical trials may provide some new treatment options, especially in cases of drug resistance. Everyone’s constitution is different and their resistance to drugs is also different. If drug resistance develops after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.
The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)